Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.

OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

OpenAI CEO Sam Altman will brief U.S. officials on super-agents—AI systems set to revolutionize software development, finance, and event planning.

Sam Altman has told OpenAI fans to lower their expectations after rumors the company had achieved AGI went viral on X.

The latest spat began after Altman joined Trump, SoftBank CEO Masayoshi Son, and Oracle Chairman Larry Ellison in a White House ceremony on Tuesday to announce the launch of Stargate, a $500 billion venture to advance the United States’ artificial intelligence infrastructure.

Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in funding to support its research. The Financial Times today cited sources as saying that Sam Altman is participating in the investment. He previously provided the initial $180 million funding round that helped launch Retro.

"And of course it's smarter than us. Of course, it can do things we can't, but also who really cares? I think it's only weird for us in this one transition time."

It’s the latest clash in a feud between the two tech billionaires that started on OpenAI’s board and is now testing Musk’s influence with the new president.

Donald Trump has announced the 500 billion US dollar AI data center. However, only OpenAI is set to benefit from this.

It's Musk vs Altman - again. But look away from the griping and sniping and the more interesting developments relate to Microsoft and OpenAI redefining their partnership.

OpenAI CEO Sam Altman surprised the tech world on Thursday with the launch of Operator, his company’s first AI agent that can act autonomously on the web. However, OpenAI is not the only venture of Altman’s that’s focused on AI agents.